Pharma Stocks
-
Is pharma packaging demand strong enough to drive sustained ga
With global biopharma growth fueling demand for specialized packaging, you need to know if Gerresheimer’s position delivers reliable returns for…
Read More » -
Piramal Pharma Ltd Technical Momentum Shifts Amid Mixed M…
Technical Trend Overview and Price Movement The pharmaceutical and biotechnology company, currently priced at ₹148.55, has seen its technical trend…
Read More » -
Buyback alert! Last date to buy Aurobindo Pharma shares for Rs 800-crore share buyback. Check details
Investors looking to participate in Aurobindo Pharma‘s share buyback worth Rs 800 crore will likely have to purchase the shares…
Read More » -
TRAWS PHARMA ($TRAW) Releases Q4 2025 Earnings
By: Quiver EarningsTracker Posted: an hour ago / April 15, 2026 8:30 p.m. UTC TRAWS PHARMA ($TRAW) posted quarterly earnings…
Read More » -
Luye Pharma (02186.HK) LY03017 Completes First Patient Enrollment in China Phase II Clinical Trial AASTOCKS Financial News
You expressly agree that the use of this app/website is at your sole risk. AASTOCKS.com Limited, HKEx Information Services Limited,…
Read More » -
CSPC PHARMA (01093.HK) SYS6051 Drug Approved for Clinical Trials in China AASTOCKS Financial News
You expressly agree that the use of this app/website is at your sole risk. AASTOCKS.com Limited, HKEx Information Services Limited,…
Read More » -
Is its wide-moat pharma strategy strong enough to unlock new upsid
Sanofi’s durable competitive advantages in vaccines and rare diseases position it for steady growth amid industry shifts. For investors in…
Read More » -
Is efzofitimod’s pulmonary sarcoidosis data strong enough to u
With efzofitimod advancing in late-stage trials for pulmonary sarcoidosis, you need to know if aTyr Pharma’s immunology focus can deliver…
Read More » -
A Look At Luye Pharma Group (SEHK:2186) Valuation As LY03020 Enters Phase II For Schizophrenia
Luye Pharma Group (SEHK:2186) has drawn fresh attention after reporting the first patient enrollment in a Phase II trial in…
Read More » -
Is its diversified pharma model strong enough to unlock new
You’re looking at a healthcare giant with deep roots in pharmaceuticals, medical devices, and consumer health—does this structure position it…
Read More »